Emcure Pharmaceuticals Limited · NSE: EMCURE · BSE: 544210
Emcure Pharmaceuticals
Quarterly results as filed with BSE. Latest: Q1 FY27 (Apr–Jun 2026), filed 06 Aug 2026.
Q1 FY27 · Consolidated
Revenue
2,580.45₹ Cr
+22.8% vs year ago
Net profit
292.49₹ Cr
+36.2% vs year ago
EPS, basic
15.50₹
+41.9% vs year ago
Net margin
11.3%
+1.1 pts vs year ago
Quarter by quarter
| Quarter | Revenue | YoY | Net profit | YoY | EPS (₹) | Filed |
|---|---|---|---|---|---|---|
| Q1 FY27Apr–Jun 2026 | 2,580.45 | +22.8% | 292.49 | +36.2% | 15.50 | 06 Aug 2026 |
| Q4 FY26Jan–Mar 2026 | 2,469.70 | +16.7% | 243.74 | +23.6% | 12.84 | 05 May 2026 |
| Q3 FY26Oct–Dec 2025 | 2,363.48 | +20.4% | 231.37 | +48.2% | 12.16 | 04 Feb 2026 |
| Q2 FY26Jul–Sep 2025 | 2,269.82 | +13.4% | 251.37 | +24.7% | 12.85 | 11 Nov 2025 |
| Q1 FY26Apr–Jun 2025 | 2,100.54 | +15.7% | 214.79 | +40.8% | 10.92 | 07 Aug 2025 |
| Q4 FY25Jan–Mar 2025 | 2,116.24 | — | 197.24 | — | 9.97 | 22 May 2025 |
| Q3 FY25Oct–Dec 2024 | 1,962.63 | — | 156.09 | — | 8.12 | 06 Feb 2025 |
| Q2 FY25Jul–Sep 2024 | 2,001.98 | — | 201.55 | — | 10.33 | 08 Nov 2024 |
| Q1 FY25Apr–Jun 2024 | 1,815.14 | — | 152.59 | — | 7.95 | 27 Aug 2024 |
Standalone results
| Quarter | Revenue | YoY | Net profit | YoY | EPS (₹) | Filed |
|---|---|---|---|---|---|---|
| Q1 FY27Apr–Jun 2026 | 1,450.93 | +32.3% | 200.11 | +63.0% | 10.55 | 06 Aug 2026 |
| Q4 FY26Jan–Mar 2026 | 1,467.70 | +14.8% | 233.70 | +67.5% | 12.33 | 05 May 2026 |
| Q3 FY26Oct–Dec 2025 | 1,418.31 | +37.9% | 258.85 | +415.6% | 13.65 | 04 Feb 2026 |
| Q2 FY26Jul–Sep 2025 | 1,260.60 | +14.1% | 117.62 | +35.3% | 6.21 | 11 Nov 2025 |
| Q1 FY26Apr–Jun 2025 | 1,096.57 | +13.0% | 122.79 | +203.6% | 6.48 | 07 Aug 2025 |
| Q4 FY25Jan–Mar 2025 | 1,278.19 | — | 139.56 | — | 7.37 | 22 May 2025 |
| Q3 FY25Oct–Dec 2024 | 1,028.81 | — | 50.20 | — | 2.65 | 06 Feb 2025 |
| Q2 FY25Jul–Sep 2024 | 1,104.63 | — | 86.92 | — | 4.62 | 08 Nov 2024 |
| Q1 FY25Apr–Jun 2024 | 970.29 | — | 40.45 | — | 2.23 | 27 Aug 2024 |
18 filings on record for this company.